Keyphrases
Clinical Evaluation
100%
Diabetes
100%
Clinical Analysis
100%
Meta-analysis
100%
Atrial Fibrillation
100%
Diabetic Kidney Disease
100%
Nephropathy
100%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
100%
Canagliflozin
100%
Evaluation Trial
100%
Renal Events
100%
Flutter
75%
Hazard Ratio
62%
Hemorrhagic Stroke
37%
Cardiovascular Outcome Trials
37%
Placebo
25%
Type 2 Diabetes Mellitus (T2DM)
25%
Estimated Glomerular Filtration Rate
25%
Chronic Kidney Disease
25%
Ischemic Stroke
25%
Stroke Subtypes
25%
Decreased Glomerular Filtration Rate
25%
Clear Effect
25%
Albuminuria
12%
Stroke Risk
12%
Random-effects Meta-analysis
12%
Overall Effect
12%
Inhibiting Effect
12%
Nonfatal Stroke
12%
Fatal Stroke
12%
Medicine and Dentistry
Clinical Trial
100%
Diabetes
100%
Apoplexy
100%
Meta-Analysis
100%
Atrial Fibrillation
100%
Nephropathy
100%
Diabetic Nephropathy
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Canagliflozin
100%
Hazard Ratio
38%
Glomerular Filtration Rate
30%
Cardiovascular System
23%
Cerebral Hemorrhage
23%
Maturity Onset Diabetes of the Young
15%
Placebo
15%
Brain Ischemia
15%
Chronic Kidney Disease
15%
Albuminuria
7%
Nursing and Health Professions
Meta Analysis
100%
Atrial Fibrillation
100%
Clinical Evaluation
100%
Kidney Disease
100%
Diabetic Nephropathy
100%
Cerebrovascular Accident
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Canagliflozin
100%
Hazard Ratio
38%
Estimated Glomerular Filtration Rate
30%
Brain Hemorrhage
23%
Non Insulin Dependent Diabetes Mellitus
15%
Chronic Kidney Failure
15%
Brain Ischemia
15%
Placebo
15%
Albuminuria
7%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Atrial Fibrillation
100%
Kidney Disease
100%
Diabetic Nephropathy
100%
Cerebrovascular Accident
100%
Canagliflozin
100%
Sodium Glucose Cotransporter 2 Inhibitor
100%
Brain Hemorrhage
23%
Placebo
15%
Brain Ischemia
15%
Chronic Kidney Failure
15%
Non Insulin Dependent Diabetes Mellitus
15%
Albuminuria
7%